Pharmaceutical companies invest huge amounts of money and time into the development of new medicines, yet it is the nature of the very difficult research and development (R&D) process that few candidate medicines that enter clinical studies are ultimately approved.
As the ABPI launches an update to its white paper of April 2009 ‘The stratification of disease for personalised medicines’ Dr Louise Leong looks at what has been achieved and what still needs to be done to support a stratified medicine approach in the UK.
The ABPI is hosting a workshop to facilitate discussions on how best to address the issue of historical data and disclosure requirements on Thursday 21 March.
Our industry uses digital media for a number of purposes including raising disease and treatment awareness, corporate awareness, clinical trial enrolment, recruitment and patient support.
Today, the ABPI updated its guidance on guidelines for collection of adverse events. Why is this important and what difference will it make for you?
The pharmacovigilance process can bring many challenges in ensuring patients’ personal data is held and transmitted in line with data protection legislation. To support companies and promote consistent practice, the ABPI, the Pharmaceutical Information & Pharmacovigilance Association (PIPA) and...
"What are your views on value-based pricing?" That is the question I've probably been asked more than any other since I took over as Chief Executive three months ago.
Read ABPI Chief Executive Stephen Whitehead's speech at the PharmaTimes debate with Ben Goldacre where the final vote on the motion 'Pharma is not getting its act together' swung in favour of industry.
ABPI Chief Executive Stephen Whitehead answers commonly asked questions about clinical trials.
Russell Brown’s letter to Andrew Lansley and Nicola Sturgeon calling for action to tackle medicines supply shortages is welcome. The Association of the British Pharmaceutical Industry has been calling for a solution too.